Introduction {#sec10}
============

We review a unique case of metastatic renal cell carcinoma to the thyroid 23 years after nephrectomy. The discussion will include a review metastatic renal cell carcinoma.

Case presentation {#sec1}
=================

Our patient is a 78-year-old woman with a left thyroid nodule. She is asymptomatic, euthyroid, and has no history of thyroid disease. Her only surgical history was a right nephrectomy 23 years ago, for a clear cell carcinoma, 4.6 cm in size, low grade (Fuhrman I), and without vascular, lymphatic, or capsular invasion.

The patient\'s medical and family histories are negative. On physical examination, neck examination revealed a 4.5-cm, soft, well-circumscribed nodule replacing the left lobe of the thyroid. There was no lymphadenopathy. Ultrasonographic examination showed 4.4-cm and 0.7-cm nodules in the left thyroid lobe and two 1.6-cm nodules in the right thyroid lobe.

Fine needle aspiration was performed. Although the cellularity and monomorphic cell population were consistent with a neoplastic process, the characteristic features of primary thyroid neoplasm were lacking. The constellation of cytologic features was in favor of metastatic renal cell carcinoma. The lesional cells were focally positive for renal cell carcinoma (RCC) and negative for thyroid transcription factor-1 (TTF-1) immunostains.

Once the clinical diagnosis of late metastatic RCC was established by cytopathology, the patient underwent total thyroidectomy. The left lobe was markedly enlarged and replaced by the nodule, with an intact capsule. The right lobe was normal in size with multiple small nodules. The thyroid was not adherent to any surrounding structures, and there was no lymphadenopathy.

Gross pathologic examination of the specimen revealed a markedly enlarged left lobe. Cut section revealed an extensively hemorrhagic mass with golden-orange speckles of friable tissue, akin to the conventional clear cell RCC seen in nephrectomy specimens ([Fig. 1](#fig1){ref-type="fig"}). Histologic examination showed a well-defined distinction between the tumor cells and the adjacent thyroid gland. The tumor showed nests of clear cells separated by a rich capillary network, which is the classic architecture and cellular morphology of clear cell RCC ([Fig. 2](#fig2){ref-type="fig"}). A more extensive panel of immunostains appropriately highlighted the renal origin of the tumor cells by strong positivity for RCC ([Fig. 3](#fig3){ref-type="fig"}) and CD10 as well as negativity for TTF-1, a pattern in sharp contrast with the neighboring thyroid parenchyma.

Discussion {#sec2}
==========

Thyroid nodules are quite common, occurring in up to 50% of the population, as indicated by ultrasonography. Only about 5% of these nodules are thyroid cancer. Primary thyroid carcinoma increased from 1% to almost 3% over the past 20 years with the advent of extensive imaging of the head and neck, with incidental discovery of thyroid nodules.[@bib1] Although metastatic disease to the thyroid gland is rare, when it does occur kidney is the most common primary tumor site.[@bib2] Other primary sites include melanoma, lung, breast, esophagus, and uterus; our senior author reported a rare case finding of colon cancer metastasis to the thyroid.[@bib3]

This report describes a tumor arising from the renal parenchyma; a clear cell carcinoma, which accounts for 70%-80% of all renal carcinomas. One of the common characteristics of clear cell carcinoma is its tendency to metastasize widely before giving rise to any local symptoms. In addition to the common sites, metastases from renal cancer can occur virtually anywhere in the body, including the thyroid.

When renal cell cancers recur, about 60% recur within 2 years, 70% within 3 years, 80% within 4 years, and most of the rest within 5 years. Recurrences can, however, occur many years later. It has been reported that 4%-11% of patients develop a recurrence 10 years after initial nephrectomy.[@bib4]

The prognosis after surgical excision of clear cell tumors varies with the size of the tumor, the Fuhrman grade, and the pathologic stage. Overall, approximately 20%-50% of patients will develop metastatic disease after nephrectomy.[@bib5] However, clear cell cancers \<5 cm in size, low grade (Fuhrman 1), and completely resected, carry an excellent prognosis with a recurrence rate of \<5%. This was the prognosis for our patient based on her original pathology 23 years ago.

In a 10-year review of 43 patients with metastatic disease to the thyroid gland at the Mayo clinic, Nakhjavani[@bib2] identified the kidney as the most common primary tumor site (33%), with an average time from diagnosis of the primary tumor to metastasis to the thyroid gland of 106 months. After a thorough review of the English scientific literature, we were not able to find a longer interval than our patient (23 years) from initial diagnosis of renal carcinoma to metastasis to the thyroid gland. There is no useful guidance in the literature on the extent of thyroidectomy for metastatic disease. In our case, we chose total thyroidectomy because our patient also had nodules within the contralateral lobe.

Conclusion {#sec3}
==========

High-quality cytopathology services have become extremely important in the management of thyroid nodules. Needle aspiration is an accurate, quick, and low-risk technique that may yield interesting results such as in this case. This technique served our patient well in identifying the rare finding of metastatic RCC to the thyroid 23 years after initial diagnosis.
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![Large hemorrhagic mass with focal golden yellow discoloration, similar to conventional renal cell carcinoma.](gr1){#fig1}

![Nests of clear cells traversed by a rich capillary network, hematoxylin and eosin, medium power.](gr2){#fig2}

![Strong diffuse labeling of tumor with renal cell carcinoma marker, high power.](gr3){#fig3}
